CKPT vs. BLRX, CALC, ELDN, FIXX, IMRX, GANX, RPHM, JAGX, NBRV, and KRON
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include BioLineRx (BLRX), CalciMedica (CALC), Eledon Pharmaceuticals (ELDN), Homology Medicines (FIXX), Immuneering (IMRX), Gain Therapeutics (GANX), Reneo Pharmaceuticals (RPHM), Jaguar Health (JAGX), Nabriva Therapeutics (NBRV), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership.
Checkpoint Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
BioLineRx has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%. Checkpoint Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.
In the previous week, Checkpoint Therapeutics had 6 more articles in the media than BioLineRx. MarketBeat recorded 9 mentions for Checkpoint Therapeutics and 3 mentions for BioLineRx. Checkpoint Therapeutics' average media sentiment score of 0.07 beat BioLineRx's score of -0.05 indicating that Checkpoint Therapeutics is being referred to more favorably in the media.
Checkpoint Therapeutics has higher earnings, but lower revenue than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than Checkpoint Therapeutics, indicating that it is currently the more affordable of the two stocks.
BioLineRx received 333 more outperform votes than Checkpoint Therapeutics when rated by MarketBeat users. Likewise, 73.32% of users gave BioLineRx an outperform vote while only 66.15% of users gave Checkpoint Therapeutics an outperform vote.
22.0% of Checkpoint Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 2.1% of Checkpoint Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Checkpoint Therapeutics presently has a consensus target price of $22.60, indicating a potential upside of 1,469.44%. BioLineRx has a consensus target price of $21.00, indicating a potential upside of 3,325.77%. Given BioLineRx's higher probable upside, analysts plainly believe BioLineRx is more favorable than Checkpoint Therapeutics.
Summary
Checkpoint Therapeutics beats BioLineRx on 9 of the 17 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
